Atea Pharmaceuticals shares are trading lower. The company announced topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial evaluating its oral antiviral therapy for chronic hepatitis C virus infection.

Benzinga Newsdesk www.benzinga.com Negative 47.5%

Neg 47.5% Neu 0% Pos 0%

Comments

No comments yet. Be the first!